Please assess the completion status of the following clinical trial:

Trial Title: Study Comparing Etanercept and Methotrexate vs. Methotrexate Alone in Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Satisfies the 1987 ACR Revised Criteria for Rheumatoid Arthritis~* Has RA greater than or equal to 3 months and less than or equal to 2 years~Exclusion Criteria:~* Received any previous treatment with MTX~* Received any previous treatment with ETN or other tumour necrosis factor antagonist

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1a (Type: ACTIVE_COMPARATOR): Etanercept + Methorexate for Period 1 (first 12 months) and Period 2 (Second 12 months)
- 1b (Type: ACTIVE_COMPARATOR): Etanercept + Methotrexate for Period 1 (First 12 months) and Etanercept alone for Period 2 (Second 12 months)
- 2a (Type: ACTIVE_COMPARATOR): Methotrexate alone in Period 1 (First 12 months) and etanercept + Methotrexate in Period 2 (Second 12 months)
- 2b (Type: ACTIVE_COMPARATOR): Methotrexate alone in Period 1 (First 12 months) and Methotrexate alone in Period 2 (Second 12 months)

Based on this trial design, predict the completion outcome and termination type (if applicable).